SCHEDULE 13G/A: Janus Henderson Group PLC Discloses 9.5% Passive Stake in Avidity Biosciences

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 9.5% beneficial ownership stake in Avidity Biosciences, Inc. as of March 31, 2025.

Summary

• Janus Henderson Group PLC, a Jersey-based entity, has filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Avidity Biosciences, Inc.
• As of March 31, 2025, Janus Henderson Group PLC beneficially owns an aggregate of 11,461,633 shares of Avidity Biosciences' Common Stock.
• This ownership represents 9.5% of the class of securities.
• The filing indicates that Janus Henderson Group PLC holds shared voting and shared dispositive power over all 11,461,633 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Avidity Biosciences.
• Indirect subsidiaries, JHIUS, JHIUKL, and JHIAIFML, are registered investment advisers furnishing investment advice to Managed Portfolios, with JHIUS specifically deemed beneficial owner of 11,318,280 shares, representing 9.4% of the class.

Sentiment

Score: 5

Explanation: Neutral. The document is a factual report of beneficial ownership and does not contain performance data or forward-looking statements from the issuer. The certification indicates a passive investment intent.

Positives

• The disclosure of a significant institutional stake by Janus Henderson Group PLC may indicate investor confidence in Avidity Biosciences.
• The filing certifies that the shares are held in the ordinary course of business and not for control purposes, suggesting a passive, long-term investment strategy.

Risks

• The document itself does not detail operational or financial risks specific to Avidity Biosciences.
• For Avidity Biosciences, a large passive institutional holding could lead to significant share price movements if the holder decides to adjust its position in the future.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." (Certification by Kristin Mariani, Head of North America Compliance, CCO for Janus Henderson Group PLC)

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Janus Henderson Group PLC provides transparency regarding the ownership structure of Avidity Biosciences, which can influence investor perception and potentially share price.

Key Dates

Keywords

Avidity Biosciences, Janus Henderson Group PLC, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Adviser, Passive Investment